| Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. | |
| | |
MedLine Citation:
|
PMID: 19479618 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Novel agents have demonstrated enhanced efficacy when combined with other antimyeloma agents especially dexamethasone. The steroid doses employed in myeloma regimens are often poorly tolerated. Therefore, in a phase II clinical trial we investigated the efficacy of a steroid-free combination including bortezomib, pegylated liposomal doxorubicin and thalidomide (VDT regimen). Twenty-three patients with relapsed or refractory myeloma or other plasma cell cancers were treated with the VDT regimen. Patient had a median of five prior therapies and 65.2% were refractory to their last regimen. The overall response rates were 55.5% and 22%, respectively. The median progression free survival was 10.9 months (95% CI: 7.3-15.8) and the median overall survival was 15.7 months (95% CI: 9.1-not reached). Fatigue and sensory neuropathy were the most common side effects noted. We observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma. |
| | |
Authors:
|
Asher Chanan-Khan; Kena C Miller; Laurie Musial; Swaminathan Padmanabhan; Jihnhee Yu; Sikander Ailawadhi; Taimur Sher; Alice Mohr; Zale P Bernstein; Maurice Barcos; Mehul Patel; Dan Iancu; Kelvin Lee; Myron S Czuczman |
Related Documents
:
|
12038448 - Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple ... 19451428 - Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years w... 17766658 - Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. 17606458 - Serum levels of opg, rankl and rankl/opg ratio in newly-diagnosed patients with multipl... 8010568 - Can preoperative and postoperative cea predict survival after colon cancer resection? 20041328 - Phase ii study of s-1, docetaxel and cisplatin combination chemotherapy in patients wit... |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: 50 ISSN: 1029-2403 ISO Abbreviation: Leuk. Lymphoma Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-06-26 Completed Date: 2009-09-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: England |
Other Details:
|
Languages: eng Pagination: 1096-101 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY 14051, USA. asher.chanan-khan@roswellpark.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents / administration & dosage* Boronic Acids / administration & dosage* Doxorubicin / administration & dosage, analogs & derivatives* Female Humans Male Middle Aged Multiple Myeloma / drug therapy* Polyethylene Glycols / administration & dosage* Pyrazines / administration & dosage* Remission Induction Salvage Therapy / methods Steroids / therapeutic use Thalidomide / administration & dosage* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Boronic Acids; 0/Polyethylene Glycols; 0/Pyrazines; 0/Steroids; 0/bortezomib; 0/pegylated liposomal doxorubicin; 23214-92-8/Doxorubicin; 50-35-1/Thalidomide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemothe...
Next Document: The effect of abdominal kinematic directives on respiratory behaviour in female classical singing.